‘Non-Small Cell Lung Cancer Drugs Market Worth $9.37bn In 2021’ Says Visiongain Report

16 August 2018
Pharma

Visiongain’s new report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other indicates that the non-small cell lung cancer drugs market will see $9.37bn in spending in 2021.
The Non-Small Cell Lung Cancer (NSCLC) Drugs market is estimated at $7.86bn in 2016 and is expected to grow at a CAGR of 4.9% in the first half of the forecast period. The market is expected to grow at a CAGR of 3.2% during the full forecast period. In 2016, the chemotherapy segment generated a revenue of $3.28bn and represented 41.7% of the total NSCLC drugs market
The lead analyst of this report said “We predict growth throughout the next ten years, although growth will be restrained in the second half of the forecast period, mainly due to patent expiries of leading therapies. Exciting new therapies, including the new class of immunotherapies, is gradually expected to reinvigorate growth in the years after the forecast period of this report. The years 2021-2027) represent a gap where revenues from the traditional leaders of the market will fall due to generic and biosimilar competition, and whilst pipeline therapies and other drivers will preserve revenues during this time, and even allow for slight growth, they won’t be able to sustain the growth seen in the first half of the forecast period.”
The 172-page report contains 133 charts that add visual analysis in order to explain the developing trends within the non-small cell lung cancer drugs market.
Visiongain provides revenue forecasts for the period 2017-2027 as well as qualitative analyses for the non-small cell lung cancer drugs market market and its leading therapeutic segments: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, and Other.
This report also provides revenue forecast for 11 leading drugs in the NSCLC market and discusses late-stage drug candidates that are currently being developed.
The 172-page report offers market forecasts for the leading regional and national markets: the US, Germany, France, The UK, Italy, Spain, Japan, China, Brazil, Russia, India, and RoW.
Moreover, our study also includes a SWOT of this industry and market.

The report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027: Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other report will be of value to anyone who wants to better understand the non-small cell lung cancer drugs market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the non-small cell lung cancer drugs market market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Visiongain Publishes Antiviral Drugs Treatment Market Report 2021-2031

Rising incidences of viral infection; increasing geriatric population is projected to propel the demand for anti-viral drugs; advancement in anti-viral drugs R&D is driving the market growth; and rising strategic initiatives for anti-viral drugs market is another major factor propelling the market growth worldwide are some of the major factors that propel the global antiviral drugs treatment market growth.

28 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever